Treatment of renal cell carcinoma with intra-arterial administration of SMANCS dissolved in Lipiodol.
Treatment of renal cell carcinoma with intra-arterial administration of SMANCS dissolved in Lipiodol.
复制标题
通过动脉内注射溶解在碘化油中的 SMANCS 治疗肾细胞癌。
作者：
S. Noda;S. Konno;J. Tanaka;M. Yamada;N. Yoshitake
患有不可切除的肾透明细胞癌的患者 1 通过动脉内注射溶解在油性介质 Liiodol 中的 SMANCS（SMANCS/Lipiodol）进行治疗。之前的研究表明，通过动脉注射 SMANCS/Lipiodol 可以实现肝癌的靶向化疗。在这项研究中，使用 SMANCS/Lipiodol 治疗肾癌，并在该患者中观察到 SMANCS/Lipiodol 在肾癌中的选择性残留。患者1，经过三年零五个月的反复动脉注射药物，患者的身体状况充分恢复，肿瘤尺寸缩小，肿瘤可以切除。 2号肾癌患者（直径4厘米）通过动脉内注射SMANCS/Lipiodol进行治疗，并进行切除以预防术后复发。 90%以上的肿瘤呈现坏死。术前动脉施用 SMANCS/Lipiodol 的明确抗癌作用可以在临床和组织学上观察到。
Patients 1 with an unresectable clear-cell carcinoma of the kidney was treated by intra-arterial administration of SMANCS dissolved in an oily medium, Lioidol, (SMANCS/Lipiodol). It was previously shown that targeting chemotherapy could be achieved for hepatoma by the arterially administered SMANCS/Lipiodol. In this study, SMANCS/Lipiodol was administered for renal cancer and the selective remaining of SMANCS/Lipiodol in renal cancer was observed in this patient. Patient 1, after three years and five months of repeated arterial injection of the drug, the patient's physical condition recovered sufficiently, reduction in tumor size was observed and the tumor became resectable. Patient 2 with renal carcinoma (4 cm in diameter) was treated by intra-arterial injection of SMANCS/Lipiodol and resected for prevention of postoperative recurrence. More than 90% of the tumor showed necrosis. Definite anticancer effects of the preoperative arterial administration of SMANCS/Lipiodol can be observed both clinically and histologically.